Bayer's Two China Approvals and a 58% Trial Win Sit Alongside a Cash Flow Still in Reverse

Bayer shares drew heavy demand on Wednesday, climbing 4.1% as part of a broad rally across the DAX. Reuters attributed the market-wide appetite for risk to the Democrats' landslide in the US midterm elections and identified no company-specific trigger for the move. A separate reading of the session put the advance at 4.5%, with the quarterly figures published on Tuesday and the raised full-year guidance cited as the driving force.

Wall Street lifts its targets

Two banks raised their price objectives on Tuesday. Goldman Sachs lifted its target to EUR 66.00 from EUR 63.50 while keeping its "Buy" rating, according to dpa-AFX. UBS moved to the same EUR 66.00 mark from EUR 62.00, also reaffirming "Buy", and pointed to earnings momentum in the pharmaceuticals division following the quarterly release. Both figures are assessments rather than guaranteed price levels.

A second green light in China

Bayer announced Chinese first-line approval for Sevabertinib on Tuesday, opening an additional angle on the pharma business. The drug is cleared for adults with advanced HER2-mutated non-small cell lung cancer, with the decision resting on data from the ongoing Phase I/II SOHO-01 study. That makes it a regulatory ruling rather than a pending review — an important distinction, since approval establishes the basis for treating patients in the authorized indication but does not by itself prove any particular revenue contribution.

The nod follows the October 26 clearance for Asundexian, marketed as Sunharbo, which is designed to cut stroke risk in adults after a non-cardioembolic ischemic stroke or a high-risk TIA. Bayer described it as the world's first approved Factor XIa inhibitor. Because the two decisions cover different therapeutic areas, the company has a chance to build on several pharma advances at once — a sturdier foundation for the investment case than betting on a single compound, though neither approval on its own yields concrete earnings.

Guidance raised, cash still flowing out

The operating backdrop looks firmer. For fiscal 2026 Bayer forecasts EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion, with the pharma division's strength underpinning the upgrade. Third-quarter 2026 revenue came in at EUR 10.053 billion alongside EBITDA before special items of EUR 1.615 billion.

The financing picture is less comfortable. Free cash flow for the current year is projected at minus EUR 1.5 billion to minus EUR 0.5 billion, so even the improved outlook still anticipates an outflow. Net financial debt is expected to land between EUR 28.0 billion and EUR 29.0 billion at year-end. A higher operating result and fresh approvals do not solve that on their own; a stronger profit line would carry more weight if it also showed up in liquidity.

Courtroom and clinical catalysts

Legal risk deserves its own ledger. On October 29, every juror in the first glyphosate trial since the US Supreme Court ruling sided with Monsanto, with Bayer stating that the plaintiffs could not substantiate their claims. It is a concluded verdict, not evidence that all glyphosate exposure is behind the company.

Further data on cardiovascular disease, kidney conditions and stroke are slated for presentation at the American Heart Association's 2026 scientific sessions. Such findings can sharpen the medical outlook but cannot substitute for proof of commercial returns. The next scheduled release of fourth-quarter 2026 figures is February 24, 2027.

The question for investors is whether the pharma unit can keep carrying the improved earnings outlook and convert regulatory wins into a durable profit base — or whether the cash drain keeps the valuation capped despite the medical progress.